Amgen hit as UK suspends Tavneos for new patients
Amgen faces a widening regulatory threat to rare-disease drug Tavneos. The U.K. suspended use for new patients and set a path toward full withdrawal in March 2027, after similar Europe action and proposed U.S. withdrawal.